Bispecific Antibodies Against HIV.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Rational Design and Characterization of Trispecific Antibodies Targeting the HIV-1 Receptor and Envelope Glycoprotein.Vaccines · 2023
   Article
2. Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity.Vaccines · 2021
   Article
3. Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.Experimental biology and medicine (Maywood, N.J.) · 2020
   Review
4. Monoclonal antibodies as anti-infective products: a promising future?Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2019
   Review
5. Broadly neutralizing antibodies in HIV-1 treatment and prevention.Therapeutic advances in vaccines and immunotherapy · 2018
   Review
6. Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions.Journal of virology · 2018
   Article
7. Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.Scientific reports · 2017
   Article
8. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.International journal of molecular sciences · 2016
   Review
9. Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Frontiers in immunology · 2016
   Review
10. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.mAbs
    Review

Corrections and comments

• Comment on
  Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.2016
• Comment on
  Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as